CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
Influenza investigational vaccine GSK2340274Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00989612
NCT00989612Phase 2Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A

GlaxoSmithKline·interventional·Posted Oct 5, 2009·Updated Jan 16, 2019

In Brief

A Phase 2 clinical trial evaluating Influenza investigational vaccine GSK2340274A for Influenza. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesJapan
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 5, 2009
Enrollment StartOct 1, 2009
Primary CompletionApr 19, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.7 years ago

Interventions

Influenza investigational vaccine GSK2340274Abiological

Two intramuscular injections on Day 0 and Day 21, respectively